VARTA AG

  • WKN: A0TGJ5
  • ISIN: DE000A0TGJ55
  • Land: Deutschland

Nachricht vom 28.08.2020 | 11:58

DGAP-DD: VARTA AG english


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
28.08.2020 / 11:58
The issuer is solely responsible for the content of this announcement.

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Name and legal form: VGG GmbH

2. Reason for the notification

a) Position / status
Person closely associated with:
Title: Dr. Dr.
First name: Michael
Last name(s): Tojner
Position: Member of the administrative or supervisory body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
VARTA AG

b) LEI
529900E7KB95KOXBWP63 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE000A0TGJ55

b) Nature of the transaction
Disposal: In connection with the IPO of VARTA AG, VGG GmbH established a stock option program (MSOP) for the benefit of the members of the Management Board and certain employees of VARTA AG and its consolidated subsidiaries. A special feature of this MSOP is that it is funded solely through shares made available by the major shareholder (VGG GmbH) and not through new shares or treasury shares of VARTA AG. This notification relates to the employees' quarterly exercise option.
Transaction linked to the exercise of share option programmes

c) Price(s) and volume(s)
Price(s) Volume(s)
128.68067 EUR 91878.00 EUR

d) Aggregated information
Price Aggregated volume
128.68067 EUR 91878.00 EUR

e) Date of the transaction
2020-08-27; UTC+2

f) Place of the transaction
Name: XETRA
MIC: XETR



28.08.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021